<DOC>
	<DOCNO>NCT01836328</DOCNO>
	<brief_summary>The majority current study regard use methadone ( MTD ) treatment cancer pain focus administration via oral route ( PO ) . The ratio consider VO parenteral route ( BP ) 2:1 . Academic literature assume ratio BP VO 1:2 . In unit , use MTD context ROP last opioid . If face situation good control pain MTD BP , usually move VO . We observe traditional ratio tend produce certain toxicity problem . Because , propose new ratio conversion PAR MTD oral MTD , i.e . 1:1.2</brief_summary>
	<brief_title>Conversion From Parenteral Oral Methadone .</brief_title>
	<detailed_description>OBJECTIVE : To compare different ratio conversion MTD VP MTD PO . To verify presence low toxicity ratio 1:1.2 1:2 still maintain good control pain patient advance cancer hospitalize different palliative care unit . METHODOLOGY : Prospective randomize single blind study patient cancer pain treat parenteral MTD would move MTD oral provide good control pain . The patient randomly split two group : ( Group A = ratio 1:1.2 Group B=ratio 1:2 ) . Patients evaluate two day switch apply , day change 3 day post-ROP . The patient display significant toxicity and/or bad analgesic control within first 72 hour post-ROP consider negative case . The size sample require include 44 patient distribute balanced group order obtain size effect 45 % statistical power 80 % . The significance level 0.05 two tail . STATISTIC ANALYSIS : By mean Chi-squared compare proportion Opioid Rotation ( OR ) failure group study .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>diagnosis advance disease type malignancy ; &gt; 18 year old time inclusion ; inclusion screen phase , patient candidate pas parenteral methadone oral methadone ( MTD ) follow physician criterion . inclusion assessment phase follow : presence cancer pain control significant toxicity MTD VP 48h . Be consider controlled pain absence significant toxicity due MTD , definition give general protocol ; e ) signing informed consent form . 1. impairment cognitive status interfere assessment ; 2. diagnosis psychiatric disorder time recruitment alters ability evaluate ; 3. presence side effect due chemotherapy / radiotherapy prior change route administration , take account follow two criterion : For patient protocol successive cycle chemotherapy ( change chemotherapy regimen ) , present side effect due chemotherapy 15 day prior change route administration clinically follow recommendation 2011 4th ed Oncomecum Spanish Society Medical Oncology deem may interfere assessment primary endpoint . For patient start new protocol chemotherapy radiotherapy , submit side effect due treatment 28 day prior change route administration base clinical judgment follow recommendation Oncomecum 2011 4th ed . Spanish Society Medical Oncology deem may interfere assessment primary endpoint . 4. invasive anesthesic technique make 3 day change oral parenteral ; 5. patient agony .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Methadone</keyword>
	<keyword>Pain</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Ratio</keyword>
</DOC>